NASDAQ:ITCI

Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

$53.89

+1.04 (+1.97%)

(As of 11/30/2022 03:22 PM ET)

Add

Compare

Today's Range: $51.52
▼
$53.89
50-Day Range: $42.70
▼
$52.88
52-Week Range: $34.43
▼
$66.00

Volume: 15,719 shs
Average Volume: 699,048 shs
Market Capitalization: $5.10 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $67.50

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 29.8% Upside
$67.50 Price Target
Short Interest: Healthy
3.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: 1.38
Based on 6 Articles This Week
Insider Trading: Selling Shares
$2.97 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.87) to ($1.79) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

166th out of 1,043 stocks

Pharmaceutical Preparations Industry

61st out of 510 stocks

3.4

Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $67.50, Intra-Cellular Therapies has a forecasted upside of 29.8% from its current price of $52.02.
Amount of Analyst Coverage
Intra-Cellular Therapies has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.36% of the outstanding shares of Intra-Cellular Therapies have been sold short.
Short Interest Ratio / Days to Cover
Intra-Cellular Therapies has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Intra-Cellular Therapies has recently decreased by 21.67%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for Intra-Cellular Therapies is -1.23.

3.0

News and Social Media Coverage

News Sentiment
Intra-Cellular Therapies has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Intra-Cellular Therapies this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,973,433.00 in company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
85.48% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.87) to ($1.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -15.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -15.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

November 30, 2022 | finance.yahoo.com

Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?

November 30, 2022 | finance.yahoo.com

Intra-Cellular Therapies Has My Attention

November 26, 2022 | finance.yahoo.com

Is Intra-Cellular Therapies (ITCI) Stock a Worthy Buy?

November 23, 2022 | finance.yahoo.com

Can Intra-Cellular (ITCI) Climb 33% to Reach the Level Wall Street Analysts Expect?

November 18, 2022 | finance.yahoo.com

Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe

November 10, 2022 | finance.yahoo.com

Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences

November 7, 2022 | finance.yahoo.com

How Much Upside is Left in Intra-Cellular (ITCI)? Wall Street Analysts Think 33%

November 5, 2022 | finance.yahoo.com

The three-year returns have been fantastic for Intra-Cellular Therapies (NASDAQ:ITCI) shareholders despite underlying losses increasing

November 2, 2022 | markets.businessinsider.com

Mizuho Securities Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)

October 27, 2022 | finance.yahoo.com

Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast

October 17, 2022 | finance.yahoo.com

Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now

October 15, 2022 | seekingalpha.com

ITCI Intra-Cellular Therapies, Inc.

October 6, 2022 | finance.yahoo.com

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Profit Outlook

September 21, 2022 | thestreet.com

Intra-Cellular Therapies (ITCI) Stock Tanks on Drug Failure, JMP Securities Downgrades

September 20, 2022 | seekingalpha.com

Intra-Cellular Therapies: What Lies Ahead

September 20, 2022 | thestreet.com

Intra-Cellular Evades Scrutiny on Schizophrenia Drug Safety, Shares Plunge

September 8, 2022 | nasdaq.com

Bullish Two Hundred Day Moving Average Cross - ITCI

August 16, 2022 | nasdaq.com

Don't Ignore The Fact That This Insider Just Sold Some Shares In Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

August 16, 2022 | benzinga.com

Director Of Intra-Cellular Therapies Makes $592K Sale

August 8, 2022 | nasdaq.com

Is a Surprise Coming for Intra-Cellular (ITCI) This Earnings Season?

August 1, 2022 | finance.yahoo.com

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

July 2, 2022 | morningstar.com

Intra-Cellular Therapies Inc - Stock Trailing Returns ITCI

June 16, 2022 | apnews.com

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

June 13, 2022 | finance.yahoo.com

Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience

May 29, 2022 | finance.yahoo.com

Those who invested in Intra-Cellular Therapies (NASDAQ:ITCI) five years ago are up 457%

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings: 11/08/2021
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/07/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ITCI
CUSIP: N/A
CIK: 1567514
Web: www.intracellulartherapies.com
Phone: (464) 440-9333
Fax: 646-440-9334
Employees: 512
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $67.50
High Stock Price Forecast: $93.00
Low Stock Price Forecast: $49.00
Forecasted Upside/Downside: +25.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-284,130,000.00
Net Margins: -158.39%
Pretax Margin: -158.39%
Return on Equity: -45.52%
Return on Assets: -40.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.81
Quick Ratio: 9.51

Sales & Book Value

Annual Sales: $83.80 million
Price / Sales: 60.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.24 per share
Price / Book: 7.44

Miscellaneous

Outstanding Shares: 94,710,000
Free Float: 91,201,000
Market Cap: $5.10 billion
Optionable: Optionable
Beta: 1.15

Key Executives

Dr. Sharon Mates Ph.D. (Age 69)
Co-Founder, Chairman, CEO & Pres
Comp: $2.25M

Mr. Lawrence J. Hineline CPA (Age 66)
CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
Comp: $791.01k

Mr. Michael I. Halstead J.D. (Age 49)
Exec. VP, Gen. Counsel & Sec.
Comp: $1.08M

Dr. Suresh K. Durgam M.D. (Age 53)
Exec. VP & Chief Medical Officer
Comp: $1.03M

Mr. Mark Neumann (Age 59)
EVP & Chief Commercial Officer
Comp: $1.01M

Dr. Robert E. Davis Ph.D. (Age 71)
Sr. VP & Chief Scientific Officer

Mr. Juan Fernando Sanchez (Age 51)
VP of Corp. Communications & Investor Relations

Ms. Karen Patruno Sheehy Esq. (Age 60)
Sr. VP & Chief Compliance Officer

Dr. Michael Olchaskey
Sr. VP & Head of Regulatory Affairs

Mr. John A. Bardi
Sr. VP of Market Access, Policy & Gov. Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.
What is Intra-Cellular Therapies' stock price forecast for 2023?: 7 brokerages have issued 12 month price objectives for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $49.00 to $93.00. On average, they predict the company's stock price to reach $67.50 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.
How have ITCI shares performed in 2022?: Intra-Cellular Therapies' stock was trading at $52.34 on January 1st, 2022. Since then, ITCI shares have increased by 1.0% and is now trading at $52.85.
View the best growth stocks for 2022 here.
Are investors shorting Intra-Cellular Therapies?: Intra-Cellular Therapies saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 3,180,000 shares, a decrease of 21.7% from the October 31st total of 4,060,000 shares. Based on an average trading volume of 701,600 shares, the days-to-cover ratio is presently 4.5 days.
View Intra-Cellular Therapies' Short Interest.
When is Intra-Cellular Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ITCI earnings forecast.
How were Intra-Cellular Therapies' earnings last quarter?: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.03. The biopharmaceutical company had revenue of $22.21 million for the quarter, compared to the consensus estimate of $22.11 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 45.52% and a negative net margin of 158.39%. The firm's revenue was up 201.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.79) EPS.

What other stocks do shareholders of Intra-Cellular Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).
What is Intra-Cellular Therapies' stock symbol?: Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
Who are Intra-Cellular Therapies' major shareholders?: Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.57%), BlackRock Inc. (7.50%), Bellevue Group AG (3.52%), Alliancebernstein L.P. (2.32%), Lord Abbett & CO. LLC (2.13%) and State Street Corp (2.09%). Insiders that own company stock include Andrew Satlin, Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.
How do I buy shares of Intra-Cellular Therapies?: Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Intra-Cellular Therapies' stock price today?: One share of ITCI stock can currently be purchased for approximately $52.85.
How much money does Intra-Cellular Therapies make?: Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.01 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284,130,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.
How many employees does Intra-Cellular Therapies have?: The company employs 512 workers across the globe.
How can I contact Intra-Cellular Therapies?: Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial